Doximity’s Winning Formula: Pharma Partnerships and AI Tools Shine in Q2 2024

Doximity ($DOCS), a leading platform for U.S. physicians, reported strong results for the second quarter of fiscal year 2024, with both revenue and EBITDA significantly surpassing the previous year’s figures. This success was driven by its targeted approach through advertising agencies to pharmaceutical companies and the expansion of services to nurse practitioners (NPs). Revenue from the top 20 pharmaceutical companies increased by 24%. Additionally, the AI-powered efficiency tool, “Doximity GPT,” has garnered 600,000 users, contributing significantly to the platform’s growth. These factors position Doximity for continued expansion and future success.